| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 251 Kalmar |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 31 | 6.0% | 33 | 6.4% | 15 | 2.9% | 1 | 0.2% | . | . | 4 | 0.8% | 431 | 83.7% | 515 | 100.0% |
| ASCUS | 41 | 28.3% | 54 | 37.2% | 36 | 24.8% | . | . | . | . | 4 | 2.8% | 10 | 6.9% | 145 | 100.0% |
| LSIL | 33 | 25.2% | 40 | 30.5% | 39 | 29.8% | . | . | . | . | 6 | 4.6% | 13 | 9.9% | 131 | 100.0% |
| Unclear atypia | . | . | . | . | . | . | . | . | 1 | 50.0% | 1 | 50.0% | . | . | 2 | 100.0% |
| ASC-H | . | . | 4 | 21.1% | 15 | 78.9% | . | . | . | . | . | . | . | . | 19 | 100.0% |
| HSIL | . | . | . | . | 12 | 85.7% | . | . | 2 | 14.3% | . | . | . | . | 14 | 100.0% |
| Totalt | 105 | 12.7% | 131 | 15.9% | 117 | 14.2% | 1 | 0.1% | 3 | 0.4% | 15 | 1.8% | 454 | 55.0% | 826 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703 |